
Shares of drug developer Acelyrin SLRN.O fall 12.7% to $2.30
SLRN reiterates its planned merger with Alumis, says unsolicited buyout offer from Concentra Biosciences is not expected to result in superior proposal
Concentra last month offered to buy Acelyrin for about $300 million, according to Reuters calculations
SLRN early in February agreed to merge with Alumis in all-stock transaction
Transaction is expected to close by Q2 2025
SLRN stock has fallen 67.3% in past 12 months